INTRODUCTION
The Preprotachykinin-A (PPT) gene encodes the neuropeptides substance P, Neurokinin A, K and γ. Recent PPT gene knock-out studies in mice have resulted in the significant moderation in their ability to experience moderate to intense pain and neurogenic inflammation (Cao et al., 1998; Zimmer et al., 1998) demonstrating the functional importance of PPT, and its products, in the peripheral nervous system (PNS). The plasticity of PPT gene expression is also an excellent model for analysis of the mechanisms correlated with nerve injury such as following axotomy, e.g. PPT gene expression is dramatically down regulated whilst other neuropeptides such as Galanin are dramatically unregulated (Hökfelt et al., 1994) . In addition to the PNS, PPT mRNA has been localised to a diverse range of central nervous system (CNS) structures in the rat (Brene et al., 1990; Harlan et al., 1989; Warden and Young, 1988) and human (Hard et al., 1999) suggesting roles for the tachykinin gene peptides in the pathology of a variety of aetiologies or diseases (Kramer et al., 1998; Liu et al., 1999; Liu et al., 1999; Maubach KA et al., 1999) . For example, substance P (SP) can enhance neural growth in vitro (Iwasaki et al., 1989) , can counteract the effects of neurotoxins administered to animals (Krasnova et al., 2000) and has mnemogenic and anxiolytic properties in vivo (Hasenohrl et al., 1998) . SP/PPT expression has also been studied in response to several neurodegenerative disorders, including Parkinsons disease, (Gresch et al., 1999) Alzheimers disease, (Bouras, 1990) and Huntington disease (Richfield and Vonsattel 1997) which are all associated with a progressive loss of PPT and SP expression within the brain. Recent studies have shown a strong correlation between the incidence of epilepsy, SP and the integrity of the dentate gyrus in a rodent model Liu, 1999) . Additionally the substance P antagonist MK-869 had antidepressant effects in patients with moderate to Summary Towards an understanding of the mechanisms controlling Preprotachykinin A (PPT) expression we have generated a variety of molecular models to determine the mechanisms regulating both the tissue-specific and stimulusinducible expression of the PPT gene. The approaches used include transgenic and virus vector models complementing biochemical analysis of promoter interactions with transcription factors. We have identified and characterised a yeast artificial chromosome (YAC) containing the human PPT gene and generated transgenic mouse lines containing multiple copies of this chromosome on a normal mouse genetic background. This resulted in a pattern of expression in the nervous system remarkably similar to that reported for PPT mRNA in rodents. In addition, this transgenic model has been constructed in such a manner to allow for over expression of tachykinins based on the number of extra alleles in the transgenic mouse. These animals allow us to further examine the function of the tachykinins and acts as a useful complement to existing PPT ablated mice. In vitro we have introduced the proximal PPT promoter in reporter gene constructs into adult neurones in both DRG and the CNS by an adenoassociated virus (AAV) vector or by biolistic transfection respectively. Using the AAV vector we have demonstrated that the proximal promoter can mediate the effects of NGF in adult rat DRG. These models allow us to delineate transcriptional domains involved in the physiological and pathological expression of the PPT gene. © 2000 Harcourt Publishers Ltd severe major depression suggesting that SP may play an important role in psychiatric disorders (Kramer et al., 1998; Maubach et al., 1999) . It is likely that inappropriate expression of the PPT gene is correlated with the disease profiles in which tachykinin gene products are implicated.
To better understand the mechanisms controlling PPT expression we have generated a variety of molecular models to determine both the tissue-specific and stimulus inducible expression of the PPT gene. These include 1. a transgenic model in which a Yeast Artificial Chromosome (YAC) containing the human PPT gene drives appropriate expression of a marker gene, 2. a virus vector model (adenoassociated virus, AAV) in which the proximal rat PPT (rPPT) promoter activity is growth factor regulated, 3. introduction of reporter gene constructs into CNS cells by biolistic firing into organotypic cultures and 4. the establishment of cell line models which reproduce part of the regulation of the PPT gene observed in vivo. These methods are complemented by a biochemical approach to the characterisation and function of transcription factors that regulate the PPT promoter as previously reviewed (Fiskerstrand et al., 1996; Quinn et al., 1996) .
Transgenic mice containing yeast artificial chromosomes encompassing the human PPT gene
Molecular biology has been used to generate tools to either remove or add genetic material to selected cells of the living animal and, where appropriate, retain the ability to control transcription of the transgene. Previous work on the PPT gene involved ablation in the mouse by homologous recombination (Cao 1998; Zimmer et al., 1998) . Although suitable for analysis of tachykinin function in vivo, it was not a suitable model for analysis of mechanisms regulating transcription of the PPT gene. Several groups have previously shown that the proximal promoter of many genes linked to a marker gene can reproduce in part some of the expected endogenous expression pattern in transgenic models. However, we failed to observe expression of the β-galactosidase marker gene directed by the proximal rPPT promoter fragment (up to 5kb). This coupled with the lack of success by other groups with small rPPT promoter fragments (Mulderry et al., 1993) spurred us to use the largest PPT promoter fragment available. We screened a YAC library to identify and characterise a 380kb YAC containing the human PPT gene. The identified YAC was tagged with a bacterial β-galactosidase gene inserted in exon 7 of the PPT gene and used to generate transgenic mice, Figure 1 . Several of the lines generated were found to contain multiple copies of this YAC. These transgenic lines produced a pattern of β-galactosidase expression in the nervous system remarkably similar to that reported for PPT mRNA in the rodent, Figure 2 . Interestingly differences of β-galactosidase expression occurred where the human PPT promoter drove marker gene expression in areas of the CNS not associated with strong PPT expression in rodents but which have been shown to 2 Quinn et al. Neuropeptides (2000) express PPT in the human. These areas include the mammillary body, the cerebellum and the dentate gyrus (manuscript submitted). The expression of β-galactosidase indicates the human promoter can direct expression of the marker gene to cells that would not ordinarily express or only poorly express PPT in the mouse. This suggests that differences in the patterns of PPT expression between species, in part, may therefore be a function of promoter sequence evolution to utilise transcription factors that were originally present in that cell in a variety of species rather than novel transcription factors being expressed in the human cells. We can now deter-
Molecular models to analyse preprotachykinin-A expression and function 5
Neuropeptides ( mine tissue/lineage specific domains regulating PPT gene expression by either random deletion analysis or by targeted removal of specific domains (perhaps identified from biochemical analysis, see below) from the YAC by homologous recombination. We are currently characterising a bacterial artificial chromosome (BAC) containing the human PPT gene (in which homologous recombination is extremely efficient) and making a rat transgene containing the YAC human PPT construct. The latter might make functional studies more amenable.
Our generation of a number of transgenic mouse lines containing extra functional PPT alleles, allows us to re-examine the function of the tachykinin peptides. Conventional 'knock-out' mice are often indistinguishable or have subtle phenotypic differences from wildtype mice, probably due to compensation by some functionally related protein. Current opinion within murine genetics suggests that the over expression of genes may be a very useful complement to conventional knockouts in determining gene function (Magdaleno and Curran, 1999) . This is very clearly demonstrated in the molecular analysis of the Zipro 1 gene. A deletion of the mouse Zipro-1 gene had little or no effect, however overexpression from a BAC construct spanning the Zipro-1 locus led to obvious aberrant phenotypes during development (Yang et al., 1999) . As stated previously the introduction of the β-galactosidase gene into the human PPT gene only affected exon 7, therefore exons 3 and 6, that encode for SP and NKA respectively, are still present and expressed in our construct. We have evidence that our lines contain up to 4 copies of the human PPT gene in addition to the wild type mouse alleles. These current YAC transgenics will allow us to re-examine and further analyse the function of the PPT products whilst addressing how over-expression of the PPT gene might affect the development and function of the mouse nervous system. We can demonstrate that copy number can be manipulated in our transgenic lines by selective breeding of the appropriate lines; this will be extremely useful in correlating levels of the tachykinin peptides with the observed phenotype, Figure 3 .
Although our analysis of PPT gene expression in the YAC transgenic lines is in the preliminary stages, these mice will also be an invaluable resource for analysis of tachykinin expression and function in non-neuronal cells. An example is the stimulus inducible expression of the tachykinin YAC in non-neuronal cells in the lung in response to various challenges (personal observations).
Analysis of Stimulus Inducible Expression of the Proximal Promoter
We have demonstrated that the 5′ promoter region of the rPPT gene spanning -865 to +447 has sufficient cis-acting information to restrict this promoter activity to DRG neurones rather than non neuronal cells or the vast majority of clonal cell lines (Fiskerstrand and Quinn, 1996; Quinn et al., 1996) . We have identified multiple positive and negative regulatory elements within this PPT promoter fragment and suggested that combinatorial interactions between these regulatory elements and their bound transcription factors are involved in the regulation of this gene Mendelson et al., 1995; Mendelson et al., 1995; Fiskerstrand et al., 1999; Harrison et al., 1999; Walker et al., 2000) , Figure 4 . To further this analysis of the role of specific transcription factors in mediating the synergy between bound transcription factors regulating the promoter we have generated model systems to analyse promoter function in neurones. These models include a virus vector system, biolistic cell transfection and characterisation of cell lines that support PPT promoter function.
Adenoassociated Virus
In general, using transgenic analysis dictates that only a limited number of constructs can be addressed because of parameters such as cost, time for generation of the transgenic line and animal house space. An alternative or complementary method to address protein function is to transfect cells in vivo and in vitro with either an expression construct to overexpress the protein or ablate translation using an antisense against the gene of interest. For our transcriptional studies we would introduce a reporter gene construct to address regulation in the cell type transfected. Neurones are generally refractory to all the common transfection procedures for introduction of plasmid DNA into cells (Mulderry, 1993) . This has hindered our analysis of transcriptional control mechanisms that operate on PPT promoter activity. We have previously had to manually microinject PPT reporter gene constructs into primary cultures of DRG (Mendelson et al., 1995; . This is a very laborious, time consuming and technically demanding procedure. A major concern of the microinjection system was that although the PPT promoter demonstrated neuronal restricted expression of the reporter genes they could not be further activated by exposure to NGF (Fiskerstrand & Quinn, 1996) . We have therefore generated an adeno-associated virus (AAV) vector model to introduce PPT reporter gene constructs in vivo into specific sub-populations of neurones or primary cultures of DRG, Figure 5 . Virus vectors are increasingly being used in experimental manipulation of gene expression in the mammalian nervous system (Barkats, 1998; Neuropeptides (2000) 34 (5), 000-000 © 2000 Harcourt Publishers Ltd Fig. 5 Adeno Associated Virus Recombinant Virus Preparation The AAV vector system packages any DNA, with a size limit of 4-5 kb, that is flanked by the AAV inverted terminal repeats (ITRs). This recombinant plasmid is co-transfected with plasmid that encodes the AAV structural proteins (rep and cap) but which lacks the AAV ITRs i.e. it cannot be packaged. Following infection with Adenovirus, the recombinant AAV virions containing the reporter gene construct flanked by ITRs, can be purified. Hermens and Verhaagen, 1998) . Unlike the transgenic approach in which the genetic background of the animal may affect the function of the transgene , the virus can be used in multiple mouse strains and more importantly other species, e.g. rats, where appropriate model systems have been developed. The AAV system offers many advantages, over other virus vectors, since it is non-pathogenic, non-immunogenic, non-toxic, highly stable and can efficiently transduce post-mitotic cells (Ferrari et al., 1997; Jooss et al., 1998; Kaplitt et al., 1994) . The AAV virus vectors cannot replicate due to the lack of virus replicative machinery and infection will be limited to the site of infection. The AAV vector system is based on its ability to package any DNA, with a size limit of 4-5 kb that is bounded by the AAV inverted terminal repeats (ITRs) (Dong et al., 1996) .
We have generated an AAV vector in which the proximal promoter of the rPPT (sequence spanning -865 to +92) drives expression of the luciferase marker gene. This vector demonstrates the same cell restricted expression as that observed when the equivalent PPT promoter driving expression of a reporter gene construct was microinjected into cells (i.e. DRG but not HeLa cells support marker gene expression directed by the PPT promoter). However distinct from the microinjection data, the proximal promoter is now regulated in primary cultures of DRG by NGF (Harrison et al., 1999) . This is significant as NGF is a major regulator of sensory neuronal phenotype and specifically PPT gene expression in vitro (primary culture) and in vivo (Amann et al., 1996; Brewster et al., 1995; Vedder et al., 1993; Lindsay et al., 1989) . We can now engineer promoter deletions or generate site specific mutants of previously characterised transcription factor binding sites, in order to delineate the cis-acting elements mediating the response of the promoter to specific signal transduction pathways. There have been previous attempts to demonstrate that neuropeptide promoters such as PPT and CGRP are responsive to NGF in primary culture models. However these experiments have had limited success, and where successful have often been difficult to reproduce (Mulderry et al., 1993; Watson, 1995) . The regulation of the PPT promoter by NGF in our virus vector construct is consistent with the in vivo regulation of endogenous PPT by NGF and the demonstration of multiple NGF responsive elements within this promoter fragment when they were analysed individually in PC12 cells (Fiskerstrand & Quinn, 1996) . We hypothesise that the differences observed in NGF inducibility of the PPT proximal promoter between the AAV and microinjection models is for one of two potential reasons; 1. The microinjection may also activate stress inducible pathways that overlap those of NGF or 2. the nucleosomal structure formed on the AAV episome or after potential integration into the host genome leads to a transcriptionally active structure similar to the endogenous PPT promoter substrate regulated by NGF. In the latter scenario there are clear precedents for nucleosomal loaded plasmids being transcriptionally distinct from naked DNA (Bonilla et al., 1991; Archer et al., 1992; Jeong et al., 1994; Beato et al., 1996) . We can also analyse real time expression by changing the marker gene from luciferase to green fluorescent protein (eGFP). Double staining experiments are also in progress to determine which subpopulation of DRG neurones are regulating the tachykinin promoter in response to different growth factors.
Our construction of virus vectors with restricted expression pattern in ganglia also allows us the potential to drive expression of other proteins or therapeutic molecules rather than a marker gene, Figure 6 . We are currently using this system to express a variety of molecules including the PPT cDNA.
Biolistic firing into Organotypic Cultures
In conjunction with our collaborators we have explored the use of particle-mediated (also called biolistic) transfection to introduce plasmid constructs into neurones. In our initial studies, rat cortical brain slices endogenously expressing the preprotachykinin gene were transfected with the same PPT promoter (-865/+92) as used in both microinjection and AAV studies driving expression of the eGFP. The cortical slices were maintained in organotypic culture so that the fluorescence intensity within individual living cells could be quantified using laser scanning confocal microscopy. The slices containing the reporter gene construct were treated with a combined exposure to forskolin and elevated potassium; a treatment that increases expression of the endogenous PPT gene. This treatment increased eGFP expression supported by the proximal PPT promoter (Walker et al., 2000) . Therefore it can be demonstrated that this protocol offers an experimental approach for analysis of neural gene promoters within single neurones in real time. Similarly, these organotypic cultures could be potentially infected with AAV reporter gene vectors.
It will be of interest to compare the different approaches of introducing plasmids into neurones. For example, the virus approach offers the ability of longterm expression, presumably via either integration of the plasmid into the host genome or the generation of a 'nucleosomal' structure on an episomal plasmid. In contrast transfection of constructs into cells, both neuronal and non-neuronal, over a period of days usually leads to degradation of the plasmid and diminution of reporter gene signal. Biolistic transfection does have the advantage that standard reporter gene constructs can be used directly rather than recloning of these sequences into virus packaging constructs. In addition there is no potential of the investigator being infected with a virus particle. The latter becomes a serious consideration if the promoter is used to drive expression, for example, of a therapeutic protein for gene delivery or target validation in pharmaceutical studies, rather than a marker gene.
Immortalised Cell lines
The use of clonal cell lines to address PPT regulation had been problematic. Although several cell lines in the literature had been demonstrated to express the endogenous PPT gene, including hybrids between DRG primary cultures and neuroblastoma cells (Wood, 1990; Platika et al., 1985) we found that they did not support expression of a marker gene directed by the rPPT promoter (unpublished observations). We were subsequently able to show that the cell lines used by our group demonstrated no PPT expression by RT-PCR. Such changes in neurotransmitter expression within cell lines with passage in culture are often observed. Nevertheless, we have recently analysed cell lines that are candidates for supporting reporter gene expression directed by the rPPT promoter. These include the pancreatic cell lines RINm5F and a novel neuronal derived cell line NF2C. RINm5F had previously been shown to express the endogenous PPT gene (McGregor, 1993) and was presumed to reflect a more embryonic phenotype of pancreatic cells as it was subsequently shown that the PPT gene was expressed in the pancreas during development (McGregor et al., 1995) . The NF2C line was derived from the brain homogenate of a transgenic animal in which a temperature sensitive SV40 large T antigen is expressed from a neurofilament promoter (Kilty et al., 1999) . These cells can be passaged at the lower temperature but differentiate at the higher temperature.
These lines are able to support expression of a reporter gene directed by a fragment of the 5′ rPPT promoter. Analysis of reporter gene expression supported by various fragments of the rPPT promoter demonstrated that although -865 to +92 supported expression, addition of fragments between +92 and +447 led to repression of expression (Fiskerstrand, 1999) . This result was consistent with rPPT promoter activity in adult rat DRG neurones, as microinjection of reporter gene constructs also confirmed the existence of this repressor domain. This repression of reporter gene activity by the larger promoter fragment could be relieved totally in the RIN cell lines and partially in NF2C cells by mutating residues between +373 and +396, containing the previously proposed Octamer binding protein enhancer element (Fiskerstrand, 1999; Mendelson et al., 1998) . We have recently been able to demonstrate that the region between +376 and +396 is able to bind multiple transcription factors and that although Octamer-binding proteins can bind to this region the repression is correlated
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with the binding of another as yet uncharacterised transcription factor (Fiskerstrand, 2000) .
The co-incidence of patterns of reporter gene expression supported by the rPPT promoter between these two cell lines and DRG validates the use of these cell line model systems for studying PPT expression. Cell culture and primary culture models are useful in addressing potential transcriptional control mechanisms that regulate promoter function that would then be confirmed in vivo through the use of transgenic models or perhaps the virus vector models outlined above.
SUMMARY
Models are in place to delineate regulatory domains involved in the tissue specific and stimulus inducible expression of the PPT gene. We can now determine the role of the previously characterised transcription factors and those identified from current studies that bind to the promoter both in vivo and in vitro. All the models have their particular strengths and weakness, the in vitro models should allow for a high throughput of mutations prior to validation in a transgenic model. Further, the in vitro models are perhaps more appropriate for asking defined questions about promoter activity in a specific cell population in response to a specific challenge (stimulus inducible expression), whereas the transgenic approach helps define the function of regulatory domains in the whole animal under normal physiological stresses (tissue/lineage specific expression). Our transgenic models that contain multiple copies of the human allele should allow us to further analyse tachykinin function. We are currently trying to make both mutations of regulatory domains and deletion of specific tachykinin peptides in the YAC and AAV vectors, the latter deletions are to address the role of solely substance P or NKA. Complementation of the recent knock-out mouse models for the PPT gene should allow for easier analysis of function.
